Smoking Habit and Respiratory Function Predict Patients' Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage.
NSCLC
data mining
personalized medicine
predictors
thoracic surgery
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Feb 2023
16 Feb 2023
Historique:
received:
29
01
2023
revised:
05
02
2023
accepted:
13
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Growing evidence suggests that sublobar resections offer more favorable outcomes than lobectomy in early-stage lung cancer surgery. However, a percentage of cases that cannot be ignored develops disease recurrence irrespective of the surgery performed with curative intent. The goal of this work is thus to compare different surgical approaches, namely, lobectomy and segmentectomy (typical and atypical) to derive prognostic and predictive markers. Here we analyzed a cohort of 153 NSCLC patients in clinical stage TNM I who underwent pulmonary resection surgery with a mediastinal hilar lymphadenectomy from January 2017 to December 2021, with an average follow-up of 25.5 months. Partition analysis was also applied to the dataset to detect outcome predictors. The results of this work showed similar OS between lobectomy and typical and atypical segmentectomy for patients with stage I NSCLC. In contrast, lobectomy was associated with a significant improvement in DFS compared with typical segmentectomy in stage IA, while in stage IB and overall, the two treatments were similar. Atypical segmentectomy showed the worst performance, especially in 3-year DFS. Quite unexpectedly, outcome predictor ranking analysis suggests a prominent role of smoking habits and respiratory function, irrespective of the tumor histotype and the patient's gender. Although the limited follow-up interval cannot allow conclusive remarks about prognosis, the results of this study suggest that both lung volumes and the degree of emphysema-related parenchymal damage are the strongest predictors of poor survival in lung cancer patients. Overall, these data point out that greater attention should be addressed to the therapeutic intervention for co-existing respiratory diseases to obtain optimal control of early lung cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Growing evidence suggests that sublobar resections offer more favorable outcomes than lobectomy in early-stage lung cancer surgery. However, a percentage of cases that cannot be ignored develops disease recurrence irrespective of the surgery performed with curative intent. The goal of this work is thus to compare different surgical approaches, namely, lobectomy and segmentectomy (typical and atypical) to derive prognostic and predictive markers.
PATIENTS AND METHODS
METHODS
Here we analyzed a cohort of 153 NSCLC patients in clinical stage TNM I who underwent pulmonary resection surgery with a mediastinal hilar lymphadenectomy from January 2017 to December 2021, with an average follow-up of 25.5 months. Partition analysis was also applied to the dataset to detect outcome predictors.
RESULTS
RESULTS
The results of this work showed similar OS between lobectomy and typical and atypical segmentectomy for patients with stage I NSCLC. In contrast, lobectomy was associated with a significant improvement in DFS compared with typical segmentectomy in stage IA, while in stage IB and overall, the two treatments were similar. Atypical segmentectomy showed the worst performance, especially in 3-year DFS. Quite unexpectedly, outcome predictor ranking analysis suggests a prominent role of smoking habits and respiratory function, irrespective of the tumor histotype and the patient's gender.
CONCLUSIONS
CONCLUSIONS
Although the limited follow-up interval cannot allow conclusive remarks about prognosis, the results of this study suggest that both lung volumes and the degree of emphysema-related parenchymal damage are the strongest predictors of poor survival in lung cancer patients. Overall, these data point out that greater attention should be addressed to the therapeutic intervention for co-existing respiratory diseases to obtain optimal control of early lung cancer.
Identifiants
pubmed: 36836096
pii: jcm12041561
doi: 10.3390/jcm12041561
pmc: PMC9967492
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Chron Obstruct Pulmon Dis. 2015 Dec 29;11:43-9
pubmed: 26766906
World J Surg. 2022 Dec 6;:
pubmed: 36472658
Lung Cancer. 2022 Oct;172:108-116
pubmed: 36058174
Ann Thorac Surg. 2016 Jun;101(6):2125-31
pubmed: 27016839
Ann Am Thorac Soc. 2017 Jul;14(Supplement_1):S74-S83
pubmed: 28511024
Surg Clin North Am. 2022 Jun;102(3):483-492
pubmed: 35671768
Chest. 1994 Mar;105(3):753-9
pubmed: 8131537
Lancet. 2022 Apr 23;399(10335):1607-1617
pubmed: 35461558
Br J Anaesth. 2018 Mar;120(3):484-500
pubmed: 29452805
Ann Surg Oncol. 2018 Jan;25(1):59-63
pubmed: 28251378
Semin Respir Crit Care Med. 2011 Feb;32(1):10-21
pubmed: 21500120
J Clin Oncol. 2016 Sep 10;34(26):3175-82
pubmed: 27382092
World J Nucl Med. 2020 Jan 29;19(2):131-136
pubmed: 32939200
J Thorac Dis. 2017 Jun;9(6):1615-1623
pubmed: 28740676
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744199
Eur J Surg Oncol. 2020 Jun;46(6):982-990
pubmed: 32113886
Ann Thorac Surg. 2006 Nov;82(5):1828-34
pubmed: 17062256
Front Oncol. 2022 Jun 30;12:825598
pubmed: 35847910
J Surg Oncol. 2023 Feb;127(2):269-274
pubmed: 36630096
Lung Cancer. 2016 Jun;96:52-5
pubmed: 27133750
Front Surg. 2022 Aug 23;9:944032
pubmed: 36090323
BMC Cancer. 2021 Jul 1;21(1):762
pubmed: 34210265
Ann Transl Med. 2019 Mar;7(Suppl 1):S50
pubmed: 31032329
Lancet Respir Med. 2018 Dec;6(12):915-924
pubmed: 30442588
Acta Inform Med. 2012 Dec;20(4):221-5
pubmed: 23378687
J Thorac Cardiovasc Surg. 1973 Oct;66(4):563-72
pubmed: 4356889
Surg Oncol. 2022 Sep;44:101840
pubmed: 36096011
Ann Surg Oncol. 2022 Mar;29(3):1868-1879
pubmed: 34613537
Perioper Med (Lond). 2018 Jan 26;7:2
pubmed: 29423173